ORMP — ORAMED PHARMACEUTICALS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1176309 ·
Last close
$3.87
Market Cap
$168.29M
52W High
$5.47
52W Low
$2.16
ADV30
132,348
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | 0 | -4,104,000 | 18,410,000 | 400,920,000 | 28,934,000 | 61,832,000 |
| Jun 2026 | 0 | 0 | -2,766,000 | 78,156,000 | 369,643,000 | 15,245,000 | 52,170,000 |
| Mar 2026 | 0 | 0 | -3,659,000 | 38,310,000 | 268,847,000 | 13,202,000 | 30,571,000 |
| Dec 2025 | 0 | 0 | -5,672,000 | 10,009,000 | 230,864,000 | 45,947,000 | 31,120,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,206,000
Investing CF
$21,502,000
Financing CF
$-16,683,000
CapEx
$-2,139,000
Dividends Paid
$-10,442,000
Buybacks
$-4,370,000
EPS Diluted TTM
$4.19
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-6,965,000
Inventory
—
Receivables
$622,000
ST Investments
$35,367,000
EBIT TTM
$62,823,000
Pretax Income TTM
$220,275,000
Interest Exp TTM
$2,558,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$0
EBITDA
$-16,080,000
Free Cash Flow
$-379,625
Enterprise Value
$109,094,848
Total Cash
$53,768,000
Total Debt
$1,530,000
Shares Out
43,485,942
Trailing EPS
$4.13
Book Value
$7.84
ROE
53.5%
ROA
-3.3%
Div Yield
6.78%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,000,000 | -15,088,000 | 64,050,000 | 230,864,000 | 31,120,000 | 199,744,000 | -9,145,000 |
| Dec 2024 | 0 | -12,781,000 | -19,060,000 | 155,278,000 | 9,931,000 | 146,265,000 | -8,412,000 |
| Dec 2023 | 1,340,000 | -15,769,000 | 5,525,000 | 220,551,000 | 57,658,000 | 163,821,000 | -10,295,000 |
| Dec 2022 | 2,703,000 | -40,598,000 | -36,561,000 | 161,642,000 | 10,486,000 | 151,812,000 | -27,918,000 |
TTM Snapshot
Revenues TTM
$-3,324,000
NetIncome TTM
$174,870,000
OpCashFlow TTM
—
Assets (Latest)
$369,643,000
Forward EPS
$-0.08
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KRRO | Korro Bio, Inc. | $169.10M | $12.32 | — |
| ELDN | Eledon Pharmaceuticals, Inc. | $167.23M | $1.98 | — |
| IFRX | InflaRx N.V. | $169.47M | $1.15 | — |
| PYXS | Pyxis Oncology, Inc. | $172.24M | $1.44 | — |
| SLGL | Sol-Gel Technologies Ltd. | $172.97M | $52.83 | — |
News headlines (Yahoo Finance, 1h cache)
Oramed: Q3 Earnings Snapshot
2026-11-12 22:36 · Yahoo
ORMP: Investment Gains Contributed to Strong 2Q26 EPS, While Inclusion in Russell Indexes Arguably Boosts Awareness
2026-08-28 09:30 · Yahoo
Oramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
2026-06-17 12:55 · Yahoo
ORMP: View Inclusion in Russell Indexes as Positive That Could Raise Awareness in Investment Community
2026-06-18 12:21 · Yahoo
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
2026-04-14 18:06 · Yahoo
Lifeward Publishes Updated Investor Presentation Highlighting Commercial Growth Strategy
2026-09-08 12:30 · Yahoo
ORMP: Strategically Acquiring Interests in Medtech & Technology Companies
2026-06-08 13:08 · Yahoo
Nano Dimension Appoints Nadav Kidron to Board of Directors to Chair Strategy and Capital Allocation Committee
2026-08-17 12:00 · Yahoo
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
2026-06-25 15:35 · Yahoo
June 2026 Penny Stocks To Watch For Potential Growth
2026-06-15 18:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.